Bactericidal activity and resistance development profiling of dalbavancin. - Wikidata - awgldk - TriplyDB

Bactericidal activity and resistance development profiling of dalbavancin.

Bactericidal activity and resistance development profiling of dalbavancin.

http://www.wikidata.org/entity/Q41839607

about

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Dalbavancin for the treatment of acute bacterial skin and skin structure infections Newer antibacterial drugs for a new century.Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.Area under the curve predictions of dalbavancin, a new lipoglycopeptide agent, using the end of intravenous infusion concentration data point by regression analyses such as linear, log-linear and power models.Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Treatment of prosthetic osteoarticular infections.Current and prospective treatments for multidrug-resistant gram-positive infections.Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift.Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.Allicin-inspired pyridyl disulfides as antimicrobial agents for multidrug-resistant Staphylococcus aureus.Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.

P2860

Q24647429-A83A41E0-DD02-43C5-8C88-2E23E62FDB86 Q26746208-34DA4A00-553F-4E65-B8FD-9F6181E895ED Q26799598-261BC5FB-3A83-4038-8369-B0013CA597C8 Q30433333-19378043-970C-46B4-8D0A-01E2B5674EA1 Q33676316-8F2C63E5-E899-47EE-A0AD-AD0A6B6E7E4F Q35168936-7EB17FF6-91D5-4335-B85F-313CF723BFD4 Q36307070-B7D72603-E864-4FD9-A5B0-EC17FFB9FBA2 Q36901937-3D6D48A1-877D-4C9A-80D5-0689482D34EE Q37071199-BFA04CBF-C613-45BB-8755-B32FED7EDD50 Q37443022-569EC15D-BF7E-4F53-BBEA-0B55001214CC Q37661510-B03372C7-E379-4AEA-8C84-0FA518574870 Q37785546-2E15606C-AC04-4237-BF60-A477DCD70E1A Q37853179-AC9EEECC-A64B-4CE1-B1BD-A9B3A32DA947 Q38123255-962B5CD1-05CE-46FB-94A5-825A86624473 Q38314386-4CCD429C-4765-41CA-BF59-FCFF6A4267D1 Q38615330-DBBFDC69-D69C-4CC2-9154-1ED678434478 Q38646905-016EC7AE-B38E-48FD-A1BA-6ED5B75FADDC Q39719043-D2C7C691-FE17-4789-95E9-54F18C40D5CE Q40719299-7F9A94AF-B3FD-4420-8CE3-669061F6EA0D Q43066197-2C39B4B7-6CB9-4461-8DAF-4A5313F0D28D Q43405839-F24200B6-1E58-4AB1-A340-6A3B4492CE49 Q43834023-52E96698-9CE6-4C22-AC3E-40AFF8D213A6 Q45072648-32734CCE-3D22-4146-8984-624194ADD183 Q47725737-EF691B56-E520-4626-832E-3E763EBF5AB6

P2860

Bactericidal activity and resistance development profiling of dalbavancin.

http://www.wikidata.org/entity/Q41839607

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Bactericidal activity and resistance development profiling of dalbavancin.

@en

type

label

Bactericidal activity and resistance development profiling of dalbavancin.

@en

prefLabel

Bactericidal activity and resistance development profiling of dalbavancin.

@en

P1433

Q41839607-1DAE11BE-BF92-45D8-B2C8-6CE5CCEDBDC9

P1476

Q41839607-0F5597B3-8DFA-486F-B239-C5EFE38B6924

P2093

Q41839607-568982F0-D201-494B-B2EB-3ED16D288F43

Q41839607-6FD324EC-BF83-4492-9E42-229650FD1B13

Q41839607-824852A2-9A33-417D-B33C-D241AB57154D

Q41839607-9718C8E3-8CFE-47FE-BB35-FEA40C809668

Q41839607-99A1077D-FD78-4C21-A8BE-F83F7BCAE9DB

P2860

Q41839607-232989A7-F71A-4609-B3C1-5D4EEEC6AA81

Q41839607-23CDC34D-3D93-470E-8D35-71A2E2CB0237

Q41839607-26B23CC3-9D19-44A1-B932-B328FBCAC6D2

Q41839607-26D97986-14EC-4334-A899-528806259B89

Q41839607-31717100-FEAE-4CBA-845F-CD4B3F6720F0

Q41839607-687D7FE6-E6A2-4985-83E7-16D2E3B206C7

Q41839607-7F10D2D6-F7DD-4CF9-A8A1-BE41B473F47F

Q41839607-80AFD71C-464F-433D-B636-AAD765FA3532

Q41839607-91A0A0C6-EE2D-4333-8C84-1DA97365D156

Q41839607-93F6D0B8-A775-4000-8B95-17AC79050DF2

P304

Q41839607-0E34A481-8FFE-495A-94F8-793895D31E8E

P31

Q41839607-A6629FD5-C48F-45E1-B89B-6C5D8924E1D2

P356

Q41839607-D1A2C733-9CD0-4511-9279-94CE8798A873

P407

Q41839607-9E89A309-7D44-4BA0-B22B-5D0C29AA8602

P433

Q41839607-28AC46BB-7BD6-4E5B-9E4C-E31971B69649

P478

Q41839607-87AAF55C-71CD-4E7E-B9CD-365302BF7026

P577

Q41839607-D5CB5091-9664-47CA-BEDF-C9F0E68466B4

P5875

Q41839607-E0172E44-8E93-47A4-965D-17F62B609C0B

P698

Q41839607-E14CC416-B86C-4F41-9C3A-8811A2A7396A

P932

Q41839607-7ACFBD22-AFC6-4E03-BB80-18B8E5A5904A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Bactericidal activity and resistance development profiling of dalbavancin.

@en

P2093

Beth P Goldstein

http://www.w3.org/2001/XMLSchema#string

Daniel F Sahm

http://www.w3.org/2001/XMLSchema#string

Daniel J Sheehan

http://www.w3.org/2001/XMLSchema#string

Deborah C Draghi

http://www.w3.org/2001/XMLSchema#string

Patricia Hogan

http://www.w3.org/2001/XMLSchema#string

P2860

Resistance studies with daptomycin

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

P304

1150-1154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00620-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6582104

http://www.w3.org/2001/XMLSchema#string

P698

17220411

http://www.w3.org/2001/XMLSchema#string

P932

1855483

http://www.w3.org/2001/XMLSchema#string